Kristin Ciriello Pothier, KPMG US, discusses biopharma dealmaking shifting toward strategic precision, with oncology, GLP-1s, and manufacturing complexity reshaping M&A valuations in 2026.
Kristin Ciriello Pothier
Advertisement
Life Sciences Sector Leader | Deal Advisory Strategist & Executor | Former Research Scientist & Precision Medicine Innovator | Author | KPMG
Articles by Kristin Ciriello Pothier
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why Eli Lilly Chose Pennsylvania for its $3.5B Facility
2
Overcoming Fill-Finish Capacity Bottlenecks in Automated Pen Injector Assembly Lines
3
Optimizing Impact for Rare Diseases
4
Implications of FDA Granting Priority Review to AZ's Ravulizumab
5